Acute Massive Haemoptysis — Comprehensive ICU Management

Definition — what makes haemoptysis "massive"

Haemoptysis is massive (also called life-threatening or exsanguinating) when the volume or the rate of bleeding threatens the airway and gas exchange. There is no single universally agreed volume threshold, and the examiner should know the spectrum:[1][3]

• Less than 30 mL per 24 hours — mild / submassive. Usually from bronchitis, mild infection, or airway inflammation; investigated as an outpatient or on the ward.
• 30-200 mL per 24 hours — moderate. Requires admission, investigation (bronchoscopy and CT), and observation; may be the harbinger of a larger bleed.
• More than 100 mL per 24 hours — the threshold many older texts use for massive, because this volume can acutely flood dependent airways.
• More than 600 mL per 24 hours (or more than 100 mL per hour) — the threshold others use for massive, approximating the volume at which gas exchange collapses.
• Any amount that threatens the airway — the modern functional definition championed by Larici and others: a patient who is aspirating, choking, or losing gas exchange from brisk bleeding has massive haemoptysis regardless of the millilitres, because the determinant of death is airway flooding, not blood loss.[1]

Why the patient dies — asphyxiation, not exsanguination

The lungs hold a small blood volume, and brisk haemoptysis rarely produces haemorrhagic shock. Instead, blood floods the tracheobronchial tree, displaces alveolar gas, abolishes gas exchange in dependent segments, and the patient arrests from hypoxaemia — typically within minutes to a couple of hours of onset. In autopsy and registry series the dominant cause of death is asphyxiation (around 80 per cent of deaths), with exsanguination accounting for only about 10 per cent and complications of treatment the remainder.[3][5]

Three consequences follow directly and shape every management decision: [1]

1. Airway protection and lung isolation come first. Securing the airway and preventing blood from flooding the contralateral lung takes priority over finding the bleeding source, reversing coagulopathy, or transferring the patient.
2. Position the bleeding side down. Gravity is a free, instant, and powerful intervention — it keeps blood in the bleeding lung and away from the good lung (see management).
3. Definitive control is by tamponade or embolisation of a bronchial artery, because the bleeding source is usually the high-pressure systemic bronchial circulation. [1]

Causes — bronchiectasis, malignancy, TB, and the fungal ball

Around 90 per cent of brisk haemoptysis originates from the BRONCHIAL arteries (systemic, high-pressure, hypertrophied by chronic inflammation), and only about 5 per cent from the pulmonary artery (e.g. a Rasmussen aneurysm eroding into a TB cavity).[2][3] The cause list, in order of frequency in most modern series:[1][2][6]

Clinical presentation

The patient usually has a known respiratory diagnosis (bronchiectasis, old TB, known cancer) but massive haemoptysis may be the first presentation. Typical features:[1][3]

• Coughing bright-red, frothy blood — often in large aliquots; froth distinguishes true haemoptysis from haematemesis
• Choking, gurgling, dyspnoea, tachypnoea — signs of airway flooding and aspiration
• Hypoxaemia (SpO2 falling), tachycardia, anxiety; shock is a late and uncommon sign (it implies exsanguination or simultaneous other pathology)
• Diffuse crackles/ronchi on auscultation as blood spreads; localised wheeze or decreased air entry may lateralise the bleed
• Features of the underlying cause: clubbing and purulent sputum (bronchiectasis), weight loss and haemoptysis on a background of smoking (cancer), TB contact or old TB scar, haematuria (pulmonary-renal syndrome) [1]

Distinguish haemoptysis from haematemesis and pseudohaemoptysis

A rapid bedside distinction matters because it changes the service you call and the airway you prepare.[1]

Severity and amount — when to declare an emergency

Declare a massive-haemoptysis emergency and mobilise the cascade the moment any of the following are present:[1][2]

1. Active brisk bleeding with choking, gurgling, or inability to clear the airway.
2. Hypoxaemia (SpO2 falling on supplemental oxygen) from aspiration of blood.
3. Estimated volume more than 100 mL in 24 hours, or more than 50 mL in a single episode, or bleeding that is accelerating.
4. Known high-risk substrate: aspergilloma, active cavitary TB, central squamous cancer, recent transthoracic biopsy, or a coagulopathy/anticoagulant. [1]

[1]

Investigations — parallel to resuscitation, never before it

Investigations must run in parallel with the airway cascade, never in sequence before it. A patient bleeding briskly is not sent to the CT scanner unsecured.[1][4]

1. Arterial blood gas — the hypoxaemia and rising CO2 of aspiration; the trend guides intubation.
2. Full blood count, group and crossmatch (4-6 units), coagulation (INR, aPTT, fibrinogen), U&E, lactate — detect coagulopathy and guide reversal and transfusion.
3. Chest X-ray — fast and lateralising in ~half of cases (opacity in the bleeding lobe); may be normal in early or central bleeds.
4. Contrast-enhanced CT chest / CT pulmonary angiography — the highest-yield localising test once the airway is secure; identifies the cause (cavity with mycetoma, tumour, bronchiectasis, AVM), bronchial artery hypertrophy (the 'shaggy' enhancing vessels), and contrast extravasation to point to the active bleeder. Perform after stabilisation or during the BAE procedure itself.[1][2]
5. Bronchoscopy — both diagnostic and therapeutic; see below.

Management — the fixed cascade

Management is a fixed cascade run in parallel by a coordinated team (ICU/anaesthetics for the airway, interventional radiology for BAE, thoracic surgery as backup). The resuscitation, airway, and referral happen simultaneously. The single overriding principle: secure the airway and protect the good lung before everything else.[1][2][5]

[1]

Step 1 in detail — airway, oxygen, position, and the call

The first sixty seconds determine survival.[3][5]

• High-flow oxygen 100% via a non-rebreather mask; switch to the circuit once intubated.
• Bleeding side down (lateral decubitus, bleeding lung dependent). If you cannot lateralise, use the history and CXR/CT; if still uncertain, lie the patient on the side the bleeding seems to come from and reassess. This single manoeuvre protects the contralateral lung from drowning.
• Suction — hard Yankauer/tip suction; blood clots fast, so keep suction available and working.
• Call for help — activate the massive-haemoptysis pathway: ICU/anaesthetics (airway), interventional radiology (BAE), thoracic surgery (backup). They should be mobilised in parallel.
• IV access x2 (large bore), bloods, crossmatch 4-6 units, coagulation — and start correcting coagulopathy at once. [1]

Step 2 in detail — choosing the tube

Step 3 in detail — bronchoscopy: rigid versus flexible

[1]

Step 4 in detail — bronchial artery embolisation

BAE is the definitive treatment for the common (bronchial-artery) massive haemoptysis, with immediate haemostasis in 70-90 per cent of patients and is the standard of care in centres with interventional radiology.[1][2]

• Technique — femoral arterial access, aortography then superselective catheterisation of the (usually hypertrophied) bronchial artery feeding the bleed, embolisation with gelatin (Gelfoam), PVA particles (150-700 micrometres), or tris-acryl gelatin microspheres; coils reserved for larger vessels or AVMs.
• Success — immediate haemostasis 70-90 per cent; recurrence (re-bleed) 10-30 per cent within ~1 year, higher with aspergilloma, active TB, and bronchopulmonary shunting. Re-bleed is managed by repeat BAE or elective surgery.
• Complications — the feared one is spinal cord ischaemia/paraplegia from inadvertent embolisation of a spinal (medullary) artery that arises from a bronchial artery; superselective catheterisation distal to any spinal branch prevents it. Others: chest pain, dysphagia, transient fever, non-target embolisation (stroke, visceral infarction), bronchial necrosis. [1]

Step 5 in detail — surgery

Surgery is reserved for failure or unavailability of BAE, a localised surgical lesion (resectable cancer, AVM, aspergilloma in an accessible cavity), or uncontrolled bleeding despite lung isolation. Lobectomy is preferred over pneumonectomy when feasible. Emergency surgery carries 20-40 per cent mortality from aspiration and instability; elective surgery for recurrent post-BAE bleeding is far safer. Lung isolation (DLT or blocker) must be in place before transfer to theatre.[1][3]

Step 6 in detail — general measures and the cause

• Reverse coagulopathy in parallel with the cascade: FFP for INR >1.5; platelets for count <50 or antiplatelet therapy; cryoprecipitate for fibrinogen <1.5 g/L; vitamin K for warfarin; idarucizumab for dabigatran; andexanet alfa for apixaban/rivaroxaban; protamine for heparin. Hold and reverse anticoagulants.
• Tranexamic acid 1 g IV — commonly given, but the evidence is weak and largely extrapolated. The HALT-IT trial (NEJM 2020) was a large randomised trial of tranexamic acid for gastrointestinal bleeding and showed no mortality benefit and a signal toward harm (venous thromboembolism, seizures); it was not a haemoptysis trial and should not be cited as haemoptysis evidence. A small Chinese RCT (Wand 2019) suggested a shorter bleed duration in mild-to-moderate haemoptysis. Use it, but know it is controversial and unproven in massive haemoptysis.
• Treat the cause — antibiotics for bacterial infection; antifungals and/or elective cavity excision for aspergilloma; definitive oncology therapy for cancer; high-dose corticosteroids, plasmapheresis, and cyclophosphamide/rituximab for diffuse alveolar haemorrhage from vasculitis/anti-GBM; anticoagulation review for PE-related bleeds. [1]

Diffuse alveolar haemorrhage — the exception that breaks the cascade

Diffuse alveolar haemorrhage (DAH) from ANCA-associated vasculitis, anti-GBM (Goodpasture) disease, or SLE produces bilateral, diffuse bleeding — there is no single bleeding lung to isolate, so the cascade above does not apply. Management is immunosuppression (high-dose methylprednisolone plus cyclophosphamide or rituximab) and plasma exchange (especially for anti-GBM), supportive ventilation with lung-protective settings, and treatment of any related renal failure. Suspect DAH when haemoptysis is bilateral on imaging, the patient has anaemia out of proportion, and there are red-cell casts/haematuria — send anti-GBM and ANCA urgently.[1]

Evidence and landmark references

[1]

Prognosis

Overall mortality ranges from 7 to 30 per cent and is driven by asphyxiation, delay to definitive control, malignancy, and coagulopathy.[1][3][6] Bronchial artery embolisation achieves immediate haemostasis in 70-90 per cent but re-bleeds in 10-30 per cent within a year (higher with aspergilloma, active TB, and bronchopulmonary shunting); recurrent bleeding is managed by repeat BAE or elective surgery. Emergency surgery carries 20-40 per cent mortality, far higher than elective resection. In non-small-cell lung cancer, a single episode of massive haemoptysis is a grim prognostic marker with ICU mortality around 30-50 per cent and short subsequent survival.[6] Predictors of a poor outcome are advanced cancer, coagulopathy or anticoagulation, a very large bleed (more than 1000 mL), bilateral aspiration, and any delay to airway protection or BAE.

Clinical pearls

Red flags

Exam practice — SAQ

References

1. [1]Larici AR, Franchi P, Occhipinti M, Contegiacomo A, del Ciello A, Calandriello L, Storto ML, Marano R, Bonomo L. Diagnosis and management of hemoptysis Diagn Interv Radiol, 2014.PMID 24808437
2. [2]Khalil A, Fedida B, Parrot A, Haddad S, Fartoukh M, Carette MF. Severe hemoptysis: From diagnosis to embolization Diagn Interv Imaging, 2015.PMID 26141487
3. [3]Jean-Baptiste E. Clinical assessment and management of massive hemoptysis Crit Care Med, 2001.PMID 11378596
4. [4]Hsiao EI, Kirsch CM, Kagawa FT, Wehner JH, Jensen WA, Baxter RB. Utility of fiberoptic bronchoscopy before bronchial artery embolization for massive hemoptysis AJR Am J Roentgenol, 2001.PMID 11566690
5. [5]Conlan AA, Hurwitz SS. Management of massive haemoptysis with the rigid bronchoscope and cold saline lavage Thorax, 1980.PMID 7268664
6. [6]Razazi K, Parrot A, Khalil A, Djibre M, Gounant V, Assouad J, Carette MF, Fartoukh M, Cadranel J. Severe haemoptysis in patients with nonsmall cell lung carcinoma Eur Respir J, 2015.PMID 25359349